Can Targeting the H+ Exchanger Be a Therapeutic Strategy?
Given its crucial role in cancer cell survival and proliferation, targeting the H+ exchanger presents a promising therapeutic strategy. Inhibitors of NHE1, for example, have shown potential in preclinical studies to reduce tumor growth and enhance the effectiveness of conventional therapies. By disrupting the pH regulation in cancer cells, these inhibitors can induce cytotoxicity and inhibit tumor progression.
